Lexatumumab, the engineered antibody, represents remarkable promise in the fight against malignant disease. This developing therapy specifically targets to lthe HER3 receptor, that is frequently overexpressed in https://bookmark-dofollow.com/story28398888/lexatumumab-an-novel-treatment-for-malignancy